Please upgrade your browser.
More targeted treatments and streamlining clinical trials are among the keys to speeding the pace of progress in finding more effective cancer treatments, a new report says.
Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma.
Organ transplant recipients in the United States double their risk of developing cancer compared to the general population. And that risk is elevated for 32 different types of cancer, according to new research.
These patients are fighting for their lives. And their fight may get harder.
Patient-friendly summaries of presentations made at the October meeting in Chicago
Is a clinical trial right for me?
Kidney Cancer Association commits $10,000.00 to research in honor of Dr. Linehan's work
Dr. Motzer delivers keynote at nation's premiere meeting of medical professionals focused on kidney cancer
|Powered by NeonCRM|